Citation Impact
Citing Papers
rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data
2014 Standout
miR-15 and miR-16 induce apoptosis by targeting BCL2
2005 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads
2012 StandoutScience
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
2002
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
2001
EGFR Antagonists in Cancer Treatment
2008 Standout
Chemosensitivity linked to p73 function
2003 StandoutNobel
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
2004
Spatio-temporal Dynamics of Protein Kinase B/Akt Signaling Revealed by a Genetically Encoded Fluorescent Reporter
2004 StandoutNobel
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
2004 Standout
Signal Transduction by the JNK Group of MAP Kinases
2000 Standout
Issues and progress with protein kinase inhibitors for cancer treatment
2003
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Physiology and immunology of the cholinergic antiinflammatory pathway
2007 Standout
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
The Inflammasome
2002 Standout
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
2007
Heat Stroke
2002 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Natural and engineered nucleic acids as tools to explore biology
2004 Nature
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
The Bcl2 family: regulators of the cellular life-or-death switch
2002 Standout
Advances of capillary electrophoresis in clinical and forensic analysis (1999-2000)
2001
An autonomous molecular computer for logical control of gene expression
2004 Nature
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
2010 StandoutNature
Atomic accuracy in predicting and designing noncanonical RNA structure
2010 StandoutNobel
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
2004
Cancer genes and the pathways they control
2004 Standout
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
2001
Antisense therapy for cancer
2005
Cisplatin resistance and oncogenes - a review
2000
RNA and Disease
2009
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
2000
Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzymea
1998
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
2003
Cytokines as Endogenous Pyrogens
1999
Oncomirs — microRNAs with a role in cancer
2006 Standout
Raf kinases: Oncogenesis and drug discovery
2006
Apoptosis
2002 Standout
Antisense therapy in oncology: new hope for an old idea?
2001
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression
1998 StandoutNature
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf
2004 StandoutNature
Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins
2012 Standout
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
2012
Overview of the clinical efficacy of investigational anticancer drugs
2003
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
2004
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Tackling the cancer stem cells — what challenges do they pose?
2014
Acute-Phase Proteins and Other Systemic Responses to Inflammation
1999 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
Inflammasomes in health and disease
2012 StandoutNature
Tumorigenesis and the angiogenic switch
2003 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cytokine induction by 41.8 °C whole body hyperthermia
1995
IL‐1: Discoveries, controversies and future directions
2010
Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
2002
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Functional Nucleic Acid Sensors
2009 Standout
Potential roles of antisense technology in cancer chemotherapy
2000
Microfluidics: Fluid physics at the nanoliter scale
2005 Standout
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
2001 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Cytokines, platelet production and hemostasis
1997
Development of anticancer drugs targeting the MAP kinase pathway
2000
The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells
1999
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
2002
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
2001
Nucleic-acid therapeutics: basic principles and recent applications
2002
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
2002
Interleukin 1α Increases Serum Leptin Concentrations in Humans
1997
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Risks, Costs, and Alternatives to Platelet Transfusions
1999
Disruption of dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor (FIH) activity
2004 StandoutNobel
Protein Kinase C ζ Transactivates Hypoxia-Inducible Factor α by Promoting Its Association with p300 in Renal Cancer
2004
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Cytokine-induced radiation protection and sensitization
1996
Works of Jon Holmlund being referenced
A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer
2004
The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin
1993
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma
2017
Antisense Approaches for the Treatment of Cancer
2000
Applying Antisense Technology
2003
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆
2003
Antisense Oligonucleotides as Inhibitors of Genes That Regulate AP-1: Pharmacology and Clinical Development
1998
A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
2001
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma
2004
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
1999
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
2000
Antigen-specific agents in development.
1997
Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)
1999
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
2008
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC
2003
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
2003